Debiopharm and Oncodesign Partner to Advance Radiopharmaceuticals in Preclinical Research

Debiopharm Research & Manufacturing S.A., a Swiss-based biopharmaceutical company, and Oncodesign Services, a contract research organization (CRO) specializing in drug discovery, have entered into a license agreement to utilize the innovative AbYlink™ technology for preclinical services. This technology, ideal for creating therapeutic and diagnostic conjugates, will be employed by Oncodesign Services to develop antibody chelator conjugates. These conjugates will be used in preclinical studies to explore the predictive effectiveness of new treatment techniques in Molecular Radiotherapy, with a particular focus on Radioimmunotherapy for cancer patients.

The AbYlink™ technology is a regio-selective bioconjugation method that offers a rapid and stable one-step process for conjugating payloads such as imaging agents to antibodies. This approach ensures that there is no impact on the antibody’s antigen-binding regions. The technology’s versatility allows for its application across various antibody isotypes and payloads, making it a valuable tool for both therapeutic and diagnostic applications.

Debiopharm's Chief Scientific Officer, Frédéric Lévy, emphasized the strategic importance of the collaboration with Oncodesign Services in expanding access to non-invasive imaging solutions. By integrating imagery into the development of new antibody-based therapeutics and antibody-drug conjugates (ADCs), the partnership aims to provide innovative solutions for biotech and pharma sectors worldwide.

Oncodesign Services' CEO, Aidan Synnott, expressed satisfaction with the integration of the AbYlink™ technology into their offerings for clients. The technology's ability to produce reproducible batches of bioconjugated antibodies and ADCs enhances the specificity and efficacy of targeted radiotherapy, a significant advantage for clients seeking advanced therapeutic solutions.

Debiopharm Research & Manufacturing specializes in producing treatments for various cancers and precocious puberty at its facility in Martigny, Switzerland. As a subsidiary of Debiopharm, the company is dedicated to developing innovative therapies that address unmet medical needs in oncology and infectious diseases. By focusing on bridging the gap between discovery and patient access, Debiopharm identifies and develops promising compounds and technologies, ensuring their clinical safety and efficacy before partnering with pharmaceutical companies for global commercialization.

Oncodesign Services, with facilities in Europe, collaborates with global biopharmaceutical partners to advance therapeutic solutions in oncology, inflammation, and infectious diseases. The company offers comprehensive services in protein sciences, structural biology, medicinal chemistry, and in vivo/in vitro pharmacology. This collaboration with Debiopharm highlights Oncodesign Services’ commitment to integrating cutting-edge technologies into their drug discovery and development processes, ultimately benefiting their biopharma clients and advancing medical innovation.

Overall, this partnership is poised to leverage the strengths of both companies in advancing Radioimmunotherapy research, potentially leading to more effective and targeted cancer treatments. By utilizing AbYlink™ technology, the collaboration aims to enhance the development of novel therapies and improve patient outcomes in the field of oncology.